All Access Articles |
- Capricor Therapeutics to Face FDA Committee Review for Duchenne Muscular Dystrophy Treatment | 2026-06-28 | PHARMACEUTICAL
- FDA Advisory Committee to Review Capricor's Duchenne Muscular Dystrophy Therapy | 2026-06-27 | PHARMACEUTICAL
- Capricor Therapeutics, Inc. Reports $318.1 Million in Cash Reserves | 2026-03-18 | UNITED STATES
- Capricor Therapeutics Prices Public Offering at $17 per Share | 2024-10-17 | PHARMACEUTICAL